ClinicalTrials.gg

Program

IBI302

Also written as “IBI302 8mg dose”, “Low dose IBI302” and “High dose IBI302”.

Its studies are mostly in Macular Degeneration · Macular Edema, led by Innovent Biologics.

Furthest: phase 3, since Jul 25, 20238 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics83 open or runningphase 3since Jul 25, 2023Jan 15, 2019Dec 31, 2026phase 2 · NCT06908876

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 15, 2019First study: phase 1 study in Neovascular Age-related Macular DegenerationFirst studyNCT03814291 · 31 enrolled · China
  2. Apr 24, 2020Phase 1 study in Neovascular Age-related Macular DegenerationNCT04370379 · 18 enrolled · China
  3. Mar 25, 2021Phase 2 study in Neovascular Age-related Macular DegenerationNCT04820452 · 231 enrolled · China
  4. Nov 15, 2021Phase 2 study in Neovascular Age-related Macular DegenerationNCT05961007 · 234 enrolled · China
  5. May 20, 2022Phase 2 study in Neovascular Age-related Macular DegenerationNCT05403749 · 132 enrolled · China
  6. Jul 25, 2023Phase 3 study in Neovascular Age-related Macular DegenerationNCT05972473 · 600 enrolled · China
  7. Mar 27, 2025Phase 2 study in Diabetic Macular OedemaNCT06908876 · 150 enrolled · China
  8. Nov 24, 2025Phase 2 study in Neovascular Age-related Macular DegenerationNCT07275840 · 800 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Diabetic Macular OedemaNCT06908876
  2. Feb 28, 2027Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationNCT05972473

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07275840Neovascular Age-related Macular Degeneration · China2RecruitingAug 30, 2026800
NCT06908876Diabetic Macular Oedema · China2Active, not recruitingDec 31, 2026150
NCT05972473Neovascular Age-related Macular Degeneration · China3Active, not recruitingFeb 28, 2027600
NCT05403749Neovascular Age-related Macular Degeneration · China2CompletedMay 13, 2024132
NCT05961007Neovascular Age-related Macular Degeneration · China2SuspendedOct 31, 2023234
NCT04820452Neovascular Age-related Macular Degeneration · China2CompletedJan 13, 2023231
NCT04370379Neovascular Age-related Macular Degeneration · China1CompletedApr 30, 202118
NCT03814291Neovascular Age-related Macular Degeneration · China1CompletedMar 5, 202031

How it is read

Names in the registry

  • “IBI302”, 9 entries
  • “IBI302 8mg dose”, 1 entry
  • “Low dose IBI302”, 1 entry
  • “High dose IBI302”, 1 entry
  • “dose 1 IBI302”, 1 entry

Codes read as this program: IBI302.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.